Targeting metabolic peculiarities: a potentially novel therapeutic approach for KRAS-mutant lung cancer?

被引：0
|
作者：
Abdel-Rahman, Omar [1 ]
机构：
[1] Ain Shams Univ, Dept Clin Oncol, Fac Med, Lotfy Elsayed St, Cairo 11511, Egypt
来源：
JOURNAL OF THORACIC DISEASE | 2016年 / 8卷 / 08期
关键词：
MEK INHIBITOR; PATIENTS PTS; NSCLC; MUTATIONS; PATHWAY;
D O I：
10.21037/jtd.2016.06.72
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：E794 / E795
页数：2
相关论文
共 50 条
  • [1] KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions
    Karimi, Nastaran
    Moghaddam, Seyed Javad
    CELLS, 2023, 12 (05)
  • [2] Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer
    Zhang Yang
    Shun-Qing Liang
    Liang Zhao
    Haitang Yang
    Thomas M. Marti
    Balazs Hegedüs
    Yanyun Gao
    Bin Zheng
    Chun Chen
    Wenxiang Wang
    Patrick Dorn
    Gregor J. Kocher
    Ralph A. Schmid
    Ren-Wang Peng
    Journal of Experimental & Clinical Cancer Research, 41
  • [3] A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
    Xiufeng Pang
    Mingyao Liu
    癌症, 2016, 35 (11) : 571 - 573
  • [4] A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
    Pang, Xiufeng
    Liu, Mingyao
    CHINESE JOURNAL OF CANCER, 2016, 35 : 92
  • [5] Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer
    Feng, Juanjuan
    Lian, Zhengke
    Xia, Xinting
    Lu, Yue
    Hu, Kewen
    Zhang, Yunpeng
    Liu, Yanan
    Hu, Longmiao
    Yuan, Kun
    Sun, Zhenliang
    Pang, Xiufeng
    ACTA PHARMACEUTICA SINICA B, 2023, 13 (03) : 1145 - 1163
  • [6] Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer
    Juanjuan Feng
    Zhengke Lian
    Xinting Xia
    Yue Lu
    Kewen Hu
    Yunpeng Zhang
    Yanan Liu
    Longmiao Hu
    Kun Yuan
    Zhenliang Sun
    Xiufeng Pang
    Acta Pharmaceutica Sinica B, 2023, (03) : 1145 - 1163
  • [7] Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer
    Yang, Zhang
    Liang, Shun-Qing
    Zhao, Liang
    Yang, Haitang
    Marti, Thomas M.
    Hegedus, Balazs
    Gao, Yanyun
    Zheng, Bin
    Chen, Chun
    Wang, Wenxiang
    Dorn, Patrick
    Kocher, Gregor J.
    Schmid, Ralph A.
    Peng, Ren-Wang
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
  • [8] A novel combination strategy to treat KRAS-mutant lung cancer
    Peng, R. -W.
    Liang, S. -Q.
    Buhrer, E. D.
    Berezowska, S.
    Marti, T. M.
    Froment, L.
    Yang, H.
    Hall, S. R.
    Vassella, E.
    Yang, Z.
    Kocher, G. J.
    Amrein, M. J.
    Riether, C.
    Ochsenbein, A. F.
    Schmid, R. A.
    BRITISH JOURNAL OF SURGERY, 2019, 106 : 19 - 19
  • [9] Closing the door on KRAS-mutant lung cancer
    Cully, Megan
    NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (11) : 747 - 747
  • [10] Closing the door on KRAS-mutant lung cancer
    Megan Cully
    Nature Reviews Drug Discovery, 2016, 15 : 747 - 747
12345